Sanofi Oncology Strategy: A New Lease On Cancer R&D
The company is rebooting after several late-stage setbacks in cancer R&D, relying on a collaboration with Regeneron to vault it into the field of immuno-oncology.
The company is rebooting after several late-stage setbacks in cancer R&D, relying on a collaboration with Regeneron to vault it into the field of immuno-oncology.